Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 12, Issue 3, Pages 479-492Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.12.3.479
Keywords
adenosine receptor; agonist; cardiac arrhythmia; cardiac perfusion imaging; colon cancer; G protein-coupled receptor; inflammation; nucleoside; pain; rheumatoid arthritis
Categories
Funding
- Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK031117, Z01DK031117] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Adenosine receptors (ARs) are a four-member subfamily of G protein-coupled receptors and are major targets of caffeine and theophylline. There are four subtypes of ARs, designated as A(1), A(2A), A(2B) and A(3). Selective agonists are now available for all four subtypes. Over a dozen of these selective agonists are now in clinical trials for various conditions, although none has received regulatory approval except for the endogenous AR agonist adenosine itself. A(1)AR agonists are in clinical trials for cardiac arrhythmias and neuropathic pain. A(2A)AR agonists are now in trials for myocardial perfusion imaging and as anti-inflammatory agents. A(2B)AR agonists are under preclinical scrutiny for potential treatment of cardiac ischemia. A(3)AR agonists are in clinical trials for the treatment of rheumatoid arthritis and colorectal cancer. The present review will mainly cover the agonists that are presently in clinical trials for various conditions and only a brief introduction will be given to major chemical classes of AR agonists presently under investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available